Literature DB >> 25023988

A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.

Victor W Ho1, Melisa J Hamilton2, Ngoc-Ha Thi Dang3, Brian E Hsu1, Hans H Adomat4, Emma S Guns4, Aalim Weljie3, Ismael Samudio1, Kevin L Bennewith3, Gerald Krystal5.   

Abstract

We recently demonstrated that both murine and human carcinomas grow significantly slower in mice on low carbohydrate (CHO), high protein diets than on isocaloric Western diets and that a further reduction in tumor growth rates occur when the low CHO diets are combined with the cyclooxygenase-2 inhibitor, celecoxib. Following upon these studies, we asked herein what effect low CHO, high protein diets, with or without celecoxib, might have on tumor metastasis. In the highly metastatic 4T1 mouse mammary tumor model, a 15% CHO, high protein diet supplemented with celecoxib (1 g/kg chow) markedly reduced lung metastases. Moreover, in longer-term studies using male Transgenic Adenocarcinoma of the Mouse Prostate mice, which are predisposed to metastatic prostate cancer, the 15% CHO diet, with and without celecoxib (0.3 g/kg chow), gave the lowest incidence of metastases, but a more moderate 25% CHO diet containing celecoxib led to the best survival. Metabolic studies with 4T1 tumors suggested that the low CHO, high protein diets may be forcing tumors to become dependent on amino acid catabolism for survival/growth. Taken together, our results suggest that a combination of a low CHO, high protein diet with celecoxib substantially reduces metastasis.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25023988      PMCID: PMC4178469          DOI: 10.1093/carcin/bgu147

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  35 in total

Review 1.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.

Authors:  Jason W Locasale; Alexandra R Grassian; Tamar Melman; Costas A Lyssiotis; Katherine R Mattaini; Adam J Bass; Gregory Heffron; Christian M Metallo; Taru Muranen; Hadar Sharfi; Atsuo T Sasaki; Dimitrios Anastasiou; Edouard Mullarky; Natalie I Vokes; Mika Sasaki; Rameen Beroukhim; Gregory Stephanopoulos; Azra H Ligon; Matthew Meyerson; Andrea L Richardson; Lynda Chin; Gerhard Wagner; John M Asara; Joan S Brugge; Lewis C Cantley; Matthew G Vander Heiden
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

3.  Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.

Authors:  Gargi D Basu; Teresa L Tinder; Judy M Bradley; Tony Tu; Christine L Hattrup; Barbara A Pockaj; Pinku Mukherjee
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

Review 4.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

5.  Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.

Authors:  Binglan Zhang; Xuelei Ma; Zhimian Li; Xiang Gao; Fengtian Wang; Lei Liu; Guobo Shen; Yaxiong Sang; Minmin Li; Yuli Li; Jingyi Zhao; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-06       Impact factor: 4.553

6.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

Authors:  Paulo A Gameiro; Juanjuan Yang; Ana M Metelo; Rocio Pérez-Carro; Rania Baker; Zongwei Wang; Alexandra Arreola; W Kimryn Rathmell; Aria Olumi; Pilar López-Larrubia; Gregory Stephanopoulos; Othon Iliopoulos
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

7.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Authors:  Toshiro Migita; Stacey Ruiz; Alessandro Fornari; Michelangelo Fiorentino; Carmen Priolo; Giorgia Zadra; Fumika Inazuka; Chiara Grisanzio; Emanuele Palescandolo; Eyoung Shin; Christopher Fiore; Wanling Xie; Andrew L Kung; Phillip G Febbo; Aravind Subramanian; Lorelei Mucci; Jing Ma; Sabina Signoretti; Meir Stampfer; William C Hahn; Stephen Finn; Massimo Loda
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

8.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

9.  Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.

Authors:  Herman A Perroud; Maria José Rico; Carlos M Alasino; Francisco Queralt; Leandro E Mainetti; Stella M Pezzotto; Viviana R Rozados; O Graciela Scharovsky
Journal:  Future Oncol       Date:  2013-03       Impact factor: 3.404

10.  Serum metabolomic profile as a means to distinguish stage of colorectal cancer.

Authors:  Farshad Farshidfar; Aalim M Weljie; Karen Kopciuk; W Don Buie; Anthony Maclean; Elijah Dixon; Francis R Sutherland; Andrea Molckovsky; Hans J Vogel; Oliver F Bathe
Journal:  Genome Med       Date:  2012-05-14       Impact factor: 11.117

View more
  8 in total

1.  Gerald Krystal, phd: The Effects of Protein and Carbohydrates on Cancer.

Authors:  Craig Gustafson
Journal:  Integr Med (Encinitas)       Date:  2015-02

2.  A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth.

Authors:  Henk M De Feyter; Kevin L Behar; Jyotsna U Rao; Kirby Madden-Hennessey; Kevan L Ip; Fahmeed Hyder; Lester R Drewes; Jean-François Geschwind; Robin A de Graaf; Douglas L Rothman
Journal:  Neuro Oncol       Date:  2016-05-03       Impact factor: 12.300

3.  The Pros and Cons of Low Carbohydrate and Ketogenic Diets in the Prevention and Treatment of Cancer.

Authors:  Ingrid Elisia; Gerald Krystal
Journal:  Front Nutr       Date:  2021-02-25

4.  Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors.

Authors:  Henry J Thompson; Scot M Sedlacek; Pamela Wolfe; Devchand Paul; Susan G Lakoski; Mary C Playdon; John N McGinley; Shawna B Matthews
Journal:  Nutrients       Date:  2015-06-26       Impact factor: 5.717

5.  All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages.

Authors:  Victor W Ho; Elyse Hofs; Ingrid Elisia; Vivian Lam; Brian E Hsu; June Lai; Beryl Luk; Ismael Samudio; Gerald Krystal
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

Review 6.  Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism.

Authors:  Qianying Zuo; Nicole Hwajin Park; Jenna Kathryn Lee; Zeynep Madak Erdogan
Journal:  Nutrients       Date:  2022-06-08       Impact factor: 6.706

Review 7.  Insulin-Lowering Diets in Metastatic Cancer.

Authors:  Sherry Shen; Neil M Iyengar
Journal:  Nutrients       Date:  2022-08-27       Impact factor: 6.706

Review 8.  Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis.

Authors:  Qiang Liu; Hongfei Zhang; Xiaoli Jiang; Caiyun Qian; Zhuoqi Liu; Daya Luo
Journal:  Mol Cancer       Date:  2017-12-02       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.